Eli Lilly and Company (NYSE:LLY):
Lilly’s Galcanezumab Significantly Reduces Number of Migraine Headache Days for Patients with Migraine: New Results Presented at AHS.
In the market the company is trading up from yesterday’s close of $80.1.
Eli Lilly and Company also recently declared a dividend paid on Friday the 9th of June 2017. The dividend was $0.520 per share for the quarter or $2.08 on an annualized basis. This dividend amount was represent a yeild of $2.62. The ex-dividend date was set for Thursday the 11th of May 2017.
Eli Lilly and Company, launched on January 17, 1901, is involved in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Business’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Business’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries..
The stock last traded at $81.04 just a bit higher than the 50 day moving average of $80.11 and barely above the 200 day moving average of $78.56. The 50 day moving average was up $0.93 or +1.16% and the 200 day average went up $2.48 or +3.16%.
Eli Lilly and Company’s P/E ratio is 39.19 and market cap is 85.60B. In the last earnings report the EPS was $2.07 and is expected to be $4.12 for the current year with 1,056,300,000 shares currently outstanding. Next quarter’s EPS is estimated at $1.05 with next year’s EPS anticipated to be $4.37.
Several investment analysts have issued ratings on Eli Lilly and Company. On November 25 the stock rating was downgraded to “Neutral” from “Overweight” in a statement from Atlantic Equities. BMO Capital lowered the price target and downgraded the stock on November 25 changing the price objective from $100.00 to $64.00 and moving the rating from “Outperform” to “Market Perform”.
On November 25 the stock rating was downgraded to “Market Perform” from “Outperform” and a price target of $64.00 was set in a report from BMO Capital. On September 8 the company was upgraded to “Overweight” from “Neutral” in an announcement from JP Morgan.
On May 2 Leerink Swann maintained a stock rating of “Outperform” but raised the price target to $91.00 from $90.00. On May 1 Credit Suisse held the company rating at “Outperform” and lowered the price target from $105.00 to $91.00.